Ischemic optic neuropathies

Neurologist

Volumn 14, Issue 6, 2008, Pages 341-354

  Luneau, Katie ^a   Newman, Nancy J ^a   Biousse, Valérie ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY EYE CENTER   (United States)

Author keywords

Arteritic ischemic optic neuropathy; Giant cell arteritis; Ischemic optic neuropathy; Nonarteritic ischemic optic neuropathy; Temporal arteritis

Indexed keywords

ACETYLSALICYLIC ACID; AGENTS ACTING ON THE EYE; ALPHA INTERFERON; AMIODARONE; ANTICOAGULANT AGENT; AZATHIOPRINE; BRIMONIDINE; C REACTIVE PROTEIN; CARBIDOPA; CORTICOSTEROID; CYCLOSPORIN; DECONGESTIVE AGENT; FIBRINOGEN; HYPERTENSIVE AGENT; INFLIXIMAB; LEVODOPA; METHOTREXATE; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENT; PHENYTOIN; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; STEROID; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASODILATOR AGENT;

ARTERITIS; CLINICAL FEATURE; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; EYE BIOPSY; EYE EDEMA; FLUORESCENCE ANGIOGRAPHY; GIANT CELL ARTERITIS; HUMAN; HYPERBARIC OXYGEN; ISCHEMIC OPTIC NEUROPATHY; LABORATORY TEST; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; STELLATE GANGLION BLOCK; TREATMENT OUTCOME; VISUAL ACUITY;

HUMANS; OPTIC NEUROPATHY, ISCHEMIC; RECURRENCE; RISK FACTORS;

EID: 57749112987     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318177394b     Document Type: Review

References (84)

1. Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, Biousse V, et al, eds. Clinical Neuro-Ophthalmology, 6th ed. Vol. 1. Philadelphia: Williams & Wilkins; 2005:349-384.
2. Ischemic Optic Neuropathy Decompression Trial (IONDT) Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273:625-632.
3. Ischemic Optic Neuropathy Decompression Trial (IONDT) Research Group. Ischemic optic neuropathy decompression trial: twenty-four-month update. Arch Ophthalmol. 2000;118:793-798.
4. Ischemic Optic Neuropathy Decompression Trial (IONDT) Research Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the ischemic optic neuropathy decompression trial. Arch Ophthalmol. 1996;114:1366-1374.
5. Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002;34:317-328.
6. Preechawat P, Bruce BB, Newman NJ, et al. Anterior ischemic optic neuropathy in patients younger than 50 Years. Am J Ophthalmol. 2007;144:953-960.
7. Hayreh SS. Anterior ischemic optic neuropathy: differentiation of arteritic from non-arteritic type and its management. Eye. 1990;4:25-41.
8. Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23:157-163.
9. Beck Rw, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology. 1987;94:1503-1508.
10. Chi T, Ritch R, Stickler D, et al. Racial differences in optic nerve head parameters. Arch Ophthalmol. 1989;107:836-839.
11. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991;109:1668-1672.
12. Horton JC. Mistaken treatment of anterior ischemic optic neuropathy with Interferon beta-1a. Ann Neurol. 2002;52:129.
13. Purvin V, King R, Kawasaki A, et al. Anterior ischemic optic neuropathy in eyes with optic disc drusen. Arch Ophthalmol. 2004;122:48-53.
14. Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;18:766-780.
15. Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol. 1997;115:1403-1407.
16. Boghen DR, Glaser JS. Ischaemic optic neuropathy. The clinical profile and history. Brain. 1975;98:689-708.
17. Mojon DS, Hedges TR, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol. 2002;120:601-605.
18. Deramo VA, Sergott RC, Augsburger JJ, et al. Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology. 2003;110:1041-1045.
19. Fry CL, Carter JE, Kanter MD, et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke. 1993;24:539-542.
20. Biousse V, Schaison M, Touboul PJ, et al. Ischemic optic neuropathy associated with internal carotid artery dissection. Arch Neurol. 1998;55:715-719.
21. Feldon SE. Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology. 1999;4:651-652.
22. Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 1999;106:739-742.
23. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocysteinemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischemic optic neuropathy. Br J Ophthalmol. 2001;85:803-806.
24. Lee AG. Prothrombotic and vascular risk factors in nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000;107:2231.
25. Biousse V. The coagulation system. J Neuroophthalmol. 2003;23:50-62.
26. Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. Curr opin ophthalmol. 1999;10:474-482.
27. Murphy MA, Murphy JF. Amiodarone and optic neuropathy: the heart of the matter. J Neuroophthalmol. 2005;25:232-326.
28. Chiari M, Manzoni GC, Van de Geijn EJ. Ischemic optic neuropathy after sumatriptan in a migraine with aura patient. Headache. 1994;34:237-238.
29. Fivgas G, Newman NJ. Anterior ischemic optic neuropathy following the use of a nasal decongestant. Am J Ophthalmol. 1999;127:104-106.
30. Lee AG, Newman NJ. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2005;140:707-708.
31. Purvin V, Kawasaki A, Borruat FX. Optic neuropathy in patients using amiodarone. Arch Ophthalmol. 2006;124:696-701.
32. Fraunfelder WF, Shults T. Non-arteritic anterior ischemic optic neuropathy, erectile dysfunction drugs, and amiodarone: is there a relationship? J Neuroophthalmol. 2006;26:1-3.
33. Lee AG, Kohnen T, Ebner R, et al. Optic neuropathy associated with laser in situ keratomileusis. J Cataract Refract Surg. 2000;26:1581-1584.
34. McCulley TJ, Lam BL, Feuer WJ. Nonarteritic anterior ischemic optic neuropathy and surgery of the anterior segment: temporal relationship analysis. Am J Ophthalmol. 2003;136:1171-1172.
35. Slavin ML, Margulis M. Anterior ischemic optic neuropathy following acute angle-closure glaucoma. Arch Ophthalmol. 2001;119:1215.
36. Arnold AC, Hepler RS, Lieber M, et al. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996;122:535-541.
37. Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996;121:450-451.
38. Johnson LN, Guy ME, Krohel GB, et al. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000;107:521-526.
39. Soheilian M, Koocheck A, Yazdani S, et al. Transvitreal optic neurotomy for nonarteritic anterior ischemic optic neuropathy. Retina. 2003;23:692-697.
40. Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION? Br J Ophthalmol. 2003;87:1193-1194.
41. Kupersmith M, Frohman L, Sanderson M, et al. Aspirin reduces the incidence of nonarteritic anterior ischemic neuropathy: a retrospective study. J Neuroophthalmol. 1997;17:250-253.
42. Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:212-217.
43. Salomon O, Huna-Baron R, Steinberg DM, et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic ischemic optic neuropathy. Eye. 1999;13:357-359.
44. Wilhelm B, Lüdtke H, Wilhelm H, et al. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomized, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol. 2006;244:551-558.
45. Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levedopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. Int J Clin Pract. 2005;59:287-290.
46. Jonas JB, Spandau UH, Harber B, et al. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:749-750.
47. Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2007;27:164-168.
48. Kelman ES. Intravitreal triamcinolone or bevecizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study? J Neuroophthalmol. 2007;27:161-163.
49. Almog Y, Goldstein M. Visual outcome in eyes with asymptomatic optic disc edema. J Neuroophthalmol. 2003;23:204-207.
50. Hayreh SS, Zimmerman MB. Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2007;114:1763-1772.
51. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
52. Weyand CM, Goronzy JJ. Medium and large vessel vasculitis. N Engl J Med. 2003;349:160-169.
53. Hayreh SS, Zimmerman B. Management of giant cell arteritis: our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239-259.
54. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521-526.
55. Liozan E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.
56. Hayreh SS, Podhajsky PA, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123:285-296.
57. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;386:266.
58. Melson MR, Weyand CM, Newman NJ, et al. The diagnosis of giant cell arteritis. Rev Neurol Dis. 2007;4:128-142.
59. Costello F, Zimmerman MB, Podhajsky PA, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14:245-257.
60. Parikh M, Miller NR, Lee AG, et al. Prevalence of normal c-reactive protein with elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113:1842-1845.
61. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:155.
62. Rahman W, Rahman FZ. Major review-giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50:415-428.
63. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484-1491.
64. Chang CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061-1064.
65. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Ophthalmologica. 2003;217:239-257.
66. Mazlumazadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. Arthritis Rheum. 2006;54:3310-3318.
67. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80:353-367.
68. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110:539-542.
69. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204-1215.
70. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.
71. Rucker CJ, Biousse V, Newman JN. Ischemic optic neuropathies. Curr Opin Neurol. 2004;17:27-35.
72. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Inflizimab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621-630.
73. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46:457-466.
74. Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol. 2001;132:743-750.
75. Hayreh SS. Posterior ischemic optic neuropathy: clinical features, pathogenesis, and management. Eye. 2004;18:1188-1206.
76. Buono LM, Foroozan R, Savino PJ, et al. Posterior ischemic optic neuropathy after hemodialysis. Ophthalmology. 2003;110:1216-1218.
77. Shapira OM, Kimmel WA, Lindsey PS, et al. Anterior ischemic optic neuropathy after open heart operations. Ann Thorac Surg. 1996;61:660-666.
78. Cheng MA, Sigurdson W, Templehoff R, et al. Visual loss after spine surgery: a survey. Neurosurgery. 2000;46:625-631.
79. Ho VT, Newman NJ, Song S, et al. Ischemic optic neuropathy following spine surgery. J Neurosurg Anesthesiol. 2005;17:38-44.
80. American Society of Anesthesiologists Task Force on Perioperative Blindness. Practice advisory for perioperative visual loss associated with spine surgery: a report by the American Society of Anesthesiologists task force on perioperative blindness. Anesthesiology. 2006;104:1319-1328.
81. Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of literature. Surv Ophthalmol. 2005;50:15-26.
82. Lee LA, Roth S, Posner KL, et al. The American Society of Anesthesiologists postoperative visual loss registry: analysis of 93 spine surgery cases with postoperative visual loss. Anesthesiology. 2006;185:652-659.
83. Lessell S. Friendly fire: neurogenic visual loss from radiation therapy. J Neuroophthalmol. 2004;24:243-250.
84. Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol. 2004;32:233-235.